Pharmacy on demand: New technologies to enable miniaturized and mobile drug manufacturing.
Purpose. Developmental pharmaceutical manufacturing systems and techniques designed to overcome the shortcomings of traditional batch processing methods are described. Summary. Conventional pharmaceutical manufacturing processes do not adequately address the needs of military and civilian patient po...
| Publicado en: | American Journal of Health-System Pharmacy Vol. 73; no. 2; pp. 45 - 55 |
|---|---|
| Autores principales: | , , |
| Formato: | pictorial tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
1/15/2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112160033&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 112160033 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10792082 1X3 jtl: American Journal of Health-System Pharmacy issn: 10792082 maglogo: N pubinfo: dt: 1/15/2016 vid: 73 iid: 2 pid: 622 pub: Oxford University Press / USA artinfo: ui: 112160033 112160033 112160033 10.2146/ajhp150639 112160033 ppf: 45 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Pharmacy on demand: New technologies to enable miniaturized and mobile drug manufacturing. aug: au: Lewin III, John J. Choi, Eugene J. Ling, Geoffrey affil: Johns Hopkins Hospital and Johns Hopkins University School of Medicine, Baltimore, MD sug: subj: Pharmaceutical Companies Drugs, Prescription Time Factors ab: Purpose. Developmental pharmaceutical manufacturing systems and techniques designed to overcome the shortcomings of traditional batch processing methods are described. Summary. Conventional pharmaceutical manufacturing processes do not adequately address the needs of military and civilian patient populations and healthcare providers. Recent advances within the Defense Advanced Research Projects Agency (DARPA) Battlefield Medicine program suggest that miniaturized, flexible platforms for end-to-end manufacturing of pharmaceuticals are possible. Advances in continuous-low synthesis, chemistry, biological engineering, and downstream processing, coupled with online analytics, automation, and enhanced process control measures, pave the way for disruptive innovation to improve the pharmaceutical supply chain and drug manufacturing base. These new technologies, along with current and ongoing advances in regulatory science, have the future potential to (1) permit "on demand" drug manufacturing on the battlefield and in other austere environments, (2) enhance the level of preparedness for chemical, biological, radiological, and nuclear threats, (3) enhance health authorities' ability to respond to natural disasters and other catastrophic events, (4) minimize shortages of drugs, (5) address gaps in the orphan drug market, (6) support and enable the continued drive toward precision medicine, and (7) enhance access to needed medications in underserved areas across the globe. Conclusion. Modular platforms under development by DARPA's Battlefield Medicine program may one day improve the safety, efficiency, and timeliness of drug manufacturing. pubtype: Academic Journal doctype: pictorial tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|